Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Mar-31-23 | Dec-31-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-Q | 8-K | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues: |
| Cardiovascular | 288.0 | | 286.7 | 266.9 | 270.2 | 259.7 | 272.3 | 241.0 |
| International | 126.2 | | 130.3 | 122.4 | 121.3 | 115.5 | 121.6 | 107.5 |
| Endoscopy | 9.6 | | 8.3 | 8.5 | 8.3 | 7.3 | 8.0 | 7.9 |
| Total revenues | 297.6 | 293.4 | 295.0 | 275.4 | 278.5 | 267.0 | 280.3 | 248.9 |
| Revenue growth [+] | 8.0% | 5.4% | 5.2% | 10.6% | 7.9% | 9.4% | 28.4% | 2.2% |
| Cardiovascular | 7.9% | | 5.3% | 10.8% | 8.1% | 9.9% | 28.3% | 2.3% |
| International | 3.1% | | 7.2% | 13.8% | 10.0% | 14.5% | 21.3% | 4.9% |
| Endoscopy | 13.1% | | 3.4% | 7.2% | 4.2% | -3.2% | 29.7% | -0.9% |
| Cost of goods sold | 159.2 | 158.9 | 159.9 | 154.5 | 149.7 | 146.5 | 156.2 | 137.0 |
| Gross profit | 138.4 | 134.6 | 135.1 | 120.9 | 128.8 | 120.5 | 124.1 | 111.9 |
| Gross margin | 46.5% | 45.9% | 45.8% | 43.9% | 46.3% | 45.1% | 44.3% | 45.0% |
| Selling, general and administrative [+] | 90.1 | 83.2 | 85.5 | 84.0 | 76.6 | 86.5 | 91.6 | 81.0 |
| General and administrative | | | | | 76.6 | | | |
| Research and development | 21.3 | 20.4 | 18.5 | 17.4 | 20.4 | 17.0 | 17.6 | 16.3 |
| Other operating expenses | 0.5 | -0.1 | 7.9 | 2.6 | 9.9 | 1.1 | 1.8 | 0.4 |
| EBITDA [+] | 46.9 | | 43.7 | 37.4 | 42.8 | 36.7 | 34.2 | 35.6 |
| EBITDA growth | 25.6% | -27.6% | 27.8% | 5.0% | -11.0% | -16.7% | 297.6% | 24.8% |
| EBITDA margin | 15.8% | 10.6% | 14.8% | 13.6% | 15.4% | 13.7% | 12.2% | 14.3% |
| Depreciation | 8.2 | | 8.4 | 8.3 | 8.6 | 8.4 | 8.6 | 8.9 |
| EBITA | 38.7 | 31.0 | 35.3 | 29.1 | 34.2 | 28.3 | 25.6 | 26.7 |
| EBITA margin | 13.0% | 10.6% | 12.0% | 10.6% | 12.3% | 10.6% | 9.1% | 10.7% |
| Amortization of intangibles | 12.3 | | 12.0 | 12.2 | 12.3 | 12.4 | 12.4 | 12.5 |
| EBIT [+] | 26.4 | 31.0 | 23.3 | 16.9 | 21.9 | 15.9 | 13.2 | 14.2 |
| EBIT growth | 56.1% | 41.4% | 76.5% | 19.1% | -10.5% | -22.8% | -187.2% | 172.6% |
| EBIT margin | 8.9% | 10.6% | 7.9% | 6.1% | 7.9% | 6.0% | 4.7% | 5.7% |
| Non-recurring items [+] | | 0.5 | | 1.7 | | | 4.3 | |
| Asset impairment | | 0.5 | | 1.7 | | | 4.3 | |
| Interest expense, net [+] | 1.9 | 2.0 | 1.3 | 0.9 | 1.0 | 1.1 | 1.3 | 1.1 |
| Interest expense | 2.0 | 2.2 | 1.3 | 1.0 | 1.1 | 1.2 | 1.4 | 1.5 |
| Interest income | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.5 |
| Other income (expense), net [+] | 1.0 | 1.8 | -1.3 | -0.2 | -0.7 | -0.6 | -0.7 | -0.4 |
| Other | 1.0 | -1.8 | -1.3 | -0.2 | -0.7 | -0.6 | -0.7 | -0.4 |
| Pre-tax income | 25.5 | 30.2 | 20.7 | 14.2 | 20.2 | 14.2 | 6.9 | 12.7 |
| Income taxes | 4.8 | -3.2 | 5.4 | 3.6 | -0.4 | 2.2 | 1.9 | 1.7 |
| Tax rate | 18.8% | | 26.1% | 25.6% | | 15.6% | 28.4% | 13.7% |
| Net income | 20.7 | 33.4 | 15.3 | 10.5 | 20.6 | 12.0 | 4.9 | 11.0 |
| Net margin | 7.0% | 11.4% | 5.2% | 3.8% | 7.4% | 4.5% | 1.8% | 4.4% |
| |
| Basic EPS [+] | $0.36 | $0.58 | $0.27 | $0.19 | $0.37 | $0.21 | $0.09 | $0.20 |
| Growth | 93.7% | 59.3% | 207.7% | -5.3% | 32.3% | -492.1% | -125.5% | -444.5% |
| Diluted EPS [+] | $0.36 | $0.58 | $0.27 | $0.18 | $0.36 | $0.21 | $0.09 | $0.19 |
| Growth | 94.1% | 60.4% | 209.4% | -4.7% | 29.5% | -483.6% | -125.0% | -436.9% |
| |
| Shares outstanding (basic) [+] | 57.4 | 57.1 | 56.7 | 56.6 | 56.1 | 56.3 | 56.1 | 55.7 |
| Growth | 1.3% | 1.7% | 1.1% | 1.6% | 1.3% | 1.4% | 1.2% | 0.9% |
| Shares outstanding (diluted) [+] | 58.2 | 58.0 | 57.6 | 57.5 | 57.4 | 57.5 | 57.3 | 57.0 |
| Growth | 1.1% | 1.1% | 0.6% | 1.0% | 3.5% | 3.7% | 3.4% | 3.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|